CN116018330B - 氘富集的吡格列酮的晶型 - Google Patents

氘富集的吡格列酮的晶型

Info

Publication number
CN116018330B
CN116018330B CN202180053547.6A CN202180053547A CN116018330B CN 116018330 B CN116018330 B CN 116018330B CN 202180053547 A CN202180053547 A CN 202180053547A CN 116018330 B CN116018330 B CN 116018330B
Authority
CN
China
Prior art keywords
crystalline
pioglitazone
hydrochloride
formula
deuterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180053547.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN116018330A (zh
Inventor
L·F·V·纳瓦雷
E·加德特
S·博尔泽
S·德维特
V·雅克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poxel SA
Original Assignee
Poxel SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel SA filed Critical Poxel SA
Publication of CN116018330A publication Critical patent/CN116018330A/zh
Application granted granted Critical
Publication of CN116018330B publication Critical patent/CN116018330B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180053547.6A 2020-06-30 2021-06-24 氘富集的吡格列酮的晶型 Active CN116018330B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063046309P 2020-06-30 2020-06-30
US202063046304P 2020-06-30 2020-06-30
US63/046,304 2020-06-30
US63/046,309 2020-06-30
US17/314,538 US11319313B2 (en) 2020-06-30 2021-05-07 Crystalline forms of deuterium-enriched pioglitazone
US17/314,538 2021-05-07
PCT/IB2021/000661 WO2022003426A1 (en) 2020-06-30 2021-06-24 Crystalline forms of deuterium-enriched pioglitazone

Publications (2)

Publication Number Publication Date
CN116018330A CN116018330A (zh) 2023-04-25
CN116018330B true CN116018330B (zh) 2026-01-09

Family

ID=79032413

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180053547.6A Active CN116018330B (zh) 2020-06-30 2021-06-24 氘富集的吡格列酮的晶型

Country Status (13)

Country Link
US (2) US11319313B2 (enExample)
EP (2) EP4285900B1 (enExample)
JP (1) JP2023532950A (enExample)
KR (1) KR20230058609A (enExample)
CN (1) CN116018330B (enExample)
AU (1) AU2021300003A1 (enExample)
BR (1) BR112022026843A2 (enExample)
CA (1) CA3184123A1 (enExample)
ES (1) ES2968512T3 (enExample)
IL (1) IL299549A (enExample)
MX (1) MX2023000189A (enExample)
TW (1) TW202216704A (enExample)
WO (1) WO2022003426A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11767317B1 (en) * 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010150014A1 (en) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4421865A (en) 1981-06-08 1983-12-20 Standard Oil Company (Sohio) Selective hydrogen-deuterium interchange using ion exchange resins
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5149820A (en) 1987-03-11 1992-09-22 Norsk Hydro A.S. Deuterated compounds
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
WO1992018501A1 (en) 1991-04-11 1992-10-29 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
KR100666887B1 (ko) 1997-10-08 2007-01-10 상꾜 가부시키가이샤 치환 축합 복소환 화합물
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
US7407978B2 (en) 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
TWI284533B (en) 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
DK1104760T3 (da) 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
AU2002337749A1 (en) * 2001-09-28 2003-04-07 Teva Pharmaceutical Industries Ltd. Pioglitazone hydrochloride
WO2003033494A1 (en) 2001-10-17 2003-04-24 Sankyo Company, Limited Benzimidazole derivative
US20030220374A1 (en) 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
GB0303609D0 (en) 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions
FR2854078B1 (fr) 2003-04-28 2008-01-11 Univ Toulouse Procede de fabrication d'une composition therapeutique immuno-stimulante.
HUP0304096A2 (hu) 2003-12-19 2005-08-29 Richter Gedeon Vegyészeti Gyár Rt. Eljárás pioglitazon hidrogénklorid előállítására és intermedierjei
BRPI0519015A2 (pt) 2004-12-15 2008-12-23 Daiichi Sankyo Co Ltd composiÇço farmacÊutica, agente profilÁtico ou agente terapÊutico, agentes para melhorar a funÇço das cÉlulas b no pÂncreas, e para a reduÇço da razço da hemoglobina glicosilada, e, usos da 5-[4-(6-metàxi-1-metil-1h-benzimidazol-2-ilmetàxi)benzi l] tiazolidina-2,4-diona ou de um sal farmacologicamente aceitÁvel da mesma e de um inibidor de fbpase, e do 2-amino-5-isobutil-4-[2-[5-(n,n'-bis((s)-1etoxicarbonil)eti l) fosfonamido] furanil} tiazol ou de um sal farmacologicamente aceitÁvel do mesmo
US7759493B2 (en) 2005-01-31 2010-07-20 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP1889618A4 (en) 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd Combined drug for treating diabetes
TW200740802A (en) 2005-07-08 2007-11-01 Sankyo Co Pharmaceutical composition containing thiazolidinedione compound
US7598273B2 (en) 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
EP1982718A4 (en) 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF CANCER
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
TW200745099A (en) 2006-03-02 2007-12-16 Sankyo Co Optically active thiazolidinedione derivatives
CA2646207C (en) 2006-03-16 2016-01-19 Metabolic Solutions Development Company Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease
TWI407959B (zh) 2006-05-23 2013-09-11 Takeda Pharmaceutical 口服製劑
TW200838512A (en) 2007-02-08 2008-10-01 Daiichi Sankyo Co Ltd Crystalline forms of a thiazolidinedione compound and manufacturing methods thereof
NZ597381A (en) 2007-09-14 2013-03-28 Metabolic Solutions Dev Co Llc Thiazolidinedione analogues for the treatment of diabetes and inflammatory diseases
US20090076093A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
US8722710B2 (en) * 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
DK2222272T3 (da) 2008-08-07 2013-02-11 Pulmagen Therapeutics Inflammation Ltd Behandling af luftvejssygdom
WO2011017244A1 (en) 2009-08-05 2011-02-10 Metabolic Solutions Development Company Polymorphs of 5-(4-(2-(5-ethylpyridin-2-yl)-2-oxoethoxy)benzyl)-1,3-thiazolidine-2,4-dione (mitoglitazone)
EP2505587A1 (en) 2009-11-26 2012-10-03 Daiichi Sankyo Company, Limited Method for manufacturing a 6-substituted-1-methyl-1h-benzimidazole derivative, and manufacturing intermediate from said method
WO2011098746A1 (en) * 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2011100685A2 (en) 2010-02-12 2011-08-18 Case Western Reserve University Methods of generating hyper inos expressing cells and uses thereof
AU2011242955A1 (en) 2010-04-19 2012-11-01 Metabolic Solutions Development Company, Llc Novel synthesis for thiazolidinedione compounds
CA2841757A1 (en) 2011-07-15 2013-01-24 Etzer Darout Gpr 119 modulators
JP2014528486A (ja) 2011-10-13 2014-10-27 ケース ウエスタン リザーブ ユニバーシティ Ｒｘｒアゴニスト化合物および方法
US20150018396A1 (en) 2012-03-08 2015-01-15 President And Fellows Of Harvard College Prevention and treatment of respiratory infection with peroxisome proliferator activator receptor delta agonist
US20140221369A1 (en) 2013-02-01 2014-08-07 Deuterx, Llc 5-deutero-2,4-thiazolidinedione and 5-deutero-2,4-oxazolidinedione derivatives and compositions comprising and methods of using the same
JP6800013B2 (ja) 2013-03-14 2020-12-16 ポクセル・ソシエテ・アノニムＰｏｘｅｌ ＳＡ 重水素化２，４−チアゾリジンジオン及び治療方法
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
US9123444B2 (en) 2014-02-03 2015-09-01 Freescale Semiconductor, Inc. Method of testing coherency of data storage in multi-processor shared memory system
SG11201608218QA (en) 2014-04-02 2016-10-28 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
WO2016153952A1 (en) 2015-03-20 2016-09-29 Deuterx, Llc Methods of treating bacterial infections and fungal infections using enantiopure deuterium-enriched pioglitazone
WO2016153948A1 (en) 2015-03-20 2016-09-29 Deuterx, Llc Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders
WO2016153951A1 (en) 2015-03-20 2016-09-29 Deuterx, Llc 5-deutero-thiazolidinyldione compounds and methods of treating medical disorders using same
WO2016153949A1 (en) 2015-03-20 2016-09-29 Deuterx, Llc 5-deutero-thiazolidine-2,4-dione compounds and methods of treating medical disorders using same
IL266530B2 (en) * 2016-11-10 2024-09-01 Galmed Res And Development Ltd Aramchol for use in fibrosis treatment
CN110357871A (zh) * 2019-07-03 2019-10-22 天津大学 二甲双胍-吡格列酮盐及其制备方法和应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010150014A1 (en) * 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment

Also Published As

Publication number Publication date
IL299549A (en) 2023-02-01
US20230074827A1 (en) 2023-03-09
US20210403464A1 (en) 2021-12-30
EP4285900A3 (en) 2024-02-07
EP4285900B1 (en) 2025-06-11
AU2021300003A1 (en) 2023-02-02
WO2022003426A1 (en) 2022-01-06
JP2023532950A (ja) 2023-08-01
MX2023000189A (es) 2023-04-27
CA3184123A1 (en) 2022-01-06
BR112022026843A2 (pt) 2023-04-25
TW202216704A (zh) 2022-05-01
EP4003514A1 (en) 2022-06-01
CN116018330A (zh) 2023-04-25
KR20230058609A (ko) 2023-05-03
EP4285900A2 (en) 2023-12-06
US11319313B2 (en) 2022-05-03
EP4003514B1 (en) 2023-10-04
ES2968512T3 (es) 2024-05-10

Similar Documents

Publication Publication Date Title
JP4532274B2 (ja) 経口用固形医薬用結晶およびそれを含む排尿障害治療用経口用固形医薬
CN115300513A (zh) 一种包含杂环类shp2抑制剂的组合物及其用途
CN102086195B (zh) 达沙替尼多晶型物及其制备方法和药用组合物
CN101891738A (zh) 达沙替尼多晶型物及其制备方法和药用组合物
EP4471021A1 (en) Salt type and crystal form of complement factor b inhibitor, and preparation method therefor and application thereof
CN106810582B (zh) 吡喃葡萄糖基衍生物的复合物、制备方法和应用
US20140221369A1 (en) 5-deutero-2,4-thiazolidinedione and 5-deutero-2,4-oxazolidinedione derivatives and compositions comprising and methods of using the same
TW202342466A (zh) 二肽基肽酶抑制劑化合物的鹽及晶型
CN116018330A (zh) 氘富集的吡格列酮的晶型
JP2021523120A (ja) セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態
EP3315493B1 (en) Phenyl amino pyrimidine compound or polymorph of salt thereof
JP5160090B2 (ja) イダゾキサン塩またはその多形体の１つをベースにした医薬組成物
EP4289856A1 (en) Crystal form of 3-hydroxy-5-pregnane-20-one derivative, and preparation method therefor and use thereof
CN115463133B (zh) 一种药物组合物、制剂及其制备方法和应用
CN102250084A (zh) 达沙替尼多晶型物及其制备方法和药用组合物
JP2010520298A (ja) ７−［（３−クロロ−６，１１−ジヒドロ−６−メチルジベンゾ［ｃ，ｆ］［１，２］チアゼピン−１１−イル）アミノ］ヘプタン酸Ｓ，Ｓ−ジオキシドの多形相ならびにそれらの製造及び使用方法
HK40104074A (en) Crystalline forms of deuterium-enriched pioglitazone
WO2017190568A1 (zh) 一种钠依赖性葡萄糖共转运蛋白抑制剂的胺溶剂合物及其制备方法和应用
HK40075224A (en) Crystalline forms of deuterium-enriched pioglitazone
HK40075224B (en) Crystalline forms of deuterium-enriched pioglitazone
US20140275268A1 (en) Novel solid forms of tacedinaline
CN106749196B (zh) 一种5-羟色胺受体激动剂
WO2023280090A1 (zh) 一种药用组合物及其制备方法和用途
CN106905301B (zh) 一种氮杂螺酮类化合物及其制备方法
HK40082657A (en) Pharmaceutical composition, formulation thereof, preparation method therefor and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant